Committee (HREC) to initiate a Phase I trial of CDI-988 for the treatment of Covid-19.
CDI-988 is an oral, broad-spectrum 3CL protease inhibitor designed using Cocrystal’s proprietary drug discovery platform technology.
The double-blind, randomised, dose-escalating, placebo-controlled study aims to to evaluate CDI-988’s tolerability, safety, and pharmacokinetics in healthy volunteers.
In August last year, Cocrystal Pharma selected hVIVO as a contract research organisation to conduct a Phase IIa human challenge trial of its oral antiviral candidate, CC-42344, for Influenza A.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.